Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.

Lanzillo, R; Quarantelli, M; Bonavita, S; Ventrella, G; Lus, G; Vacca, G; Prinster, A; Orefice, G; Tedeschi, G; Brescia Morra, V

Lanzillo, R; Quarantelli, M; Bonavita, S; Ventrella, G; Lus, G; Vacca, G; Prinster, A; Orefice, G; Tedeschi, G; Brescia Morra, V.

Affiliation

Lanzillo R; Neurological Sciences Department, Federico II University, Naples, Italy. robertalanzillo@libero.it

Acta Neurol Scand ; 126(5): 306-14, 2012 Nov.

Article in En | MEDLINE | ID: mdl-22107083

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Immunologic Factors/therapeutic use; Interferon-beta/therapeutic use; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Brain/pathology; Central Nervous System/pathology; Disability Evaluation; Disease Progression; Female; Humans; Male; Multiple Sclerosis, Relapsing-Remitting/pathology; Multiple Sclerosis, Relapsing-Remitting/prevention & control; Natalizumab; Retrospective Studies; Secondary Prevention

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interferon-beta / Multiple Sclerosis, Relapsing-Remitting / Antibodies, Monoclonal, Humanized / Immunologic Factors Type of study: Observational_studies Limits: Female / Humans / Male Language: En Journal: Acta Neurol Scand Year: 2012 Type: Article Affiliation country: Italy

Fulltext

XML

PubMed Links

Search on Google